Skip to content

Digital Pharma

Active
Private limited companyfounded 2021active for 5 yearsSlingerweg 52, 3600 Genk, Belgium10 active companies are registered at this addressKBO/BCE: BE 0771.989.346
Summary

Digital Pharma has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €294,014 and a net result of -€76,594. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 30% of 567 sector peers (NACE 63, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).

Risk analysisFollow ReportCompare
Digital PharmaActiveChecked score 83/100
Risk analysis ReportCompare

History

On 4 August 2021, Digital Pharma was incorporated as a private limited company.1 In 2026 the capital was increased by €400,581.2 Total assets went from €821,201 in 2022 to €1.4m in 2025 and headcount from 3.5 to 2.7 full-time equivalents.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 13-01-2026
  3. 3National Bank, annual accounts 2022 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
10-07
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
13-01
Gazette deed Amendment of the articles
Capital increase · Capital contribution · Authorised capital13 facts ▸
  • General meeting, 29-12-2025
  • Other provision, “verslagen bedoeld in artikel 5:121,§1, afstand verslagplicht” (deed in Dutch)
  • Capital increase, €400,581
  • Other provision, “individuele en onherroepelijke afstand van het voorkeurrecht” (deed in Dutch)
  • Capital contribution, €23,527 (3 times)
  • Capital contribution, €330,000
  • Other provision, “C, aanvaarding en plaatsing inbrengen” (deed in Dutch)
  • Other provision, “vaststelling effectieve verwezenlijking inbrengen, verwezenlijkt maar nog niet volgestort” (deed in Dutch)
  • Other provision, “kennisname verslag bevoegdheidsdelegatie, afschrift ontvangen en kennis genomen” (deed in Dutch)
  • Authorised capital, “uitbreiding”, EUR (deed in Dutch)
  • Amendment of the articles
  • Capital
  • +1 further fact in this act
2025
31-12
Financial Equity above €200,000equity €294,014
Equity rises from -€47,948 to €294,014.
30-07
NBB filing Annual accounts filed
financial year 2024 · abbreviated format
2024
26-07
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
29-01
Gazette deed Capital & shares · Amendment of the articles
Capital increase · Share issue · Declaration12 facts ▸
  • General meeting, 28-12-2023
  • Other provision, “bestuursorgaan, verslag creatie soorten aandelen” (deed in Dutch)
  • Other provision, “geen verslag bedrijfsrevisor of externe accountant vereist, geen financiële en boekhoudkundige gevolgen” (deed in Dutch)
  • Other provision, “geen andere verslagen en documenten voor te leggen, voorzitter” (deed in Dutch)
  • Capital increase, €350,000
  • Other provision, “alle aandeelhouders, C” (deed in Dutch)
  • Share issue, “C, volledig geplaatst” (deed in Dutch)
  • Declaration, “bevestiging inschrijving op alle aandelen” (deed in Dutch)
  • Capital
  • Amendment of the articles, 5
  • Amendment of the articles, 22
  • Other provision, “boeking inbrengen in geld op beschikbare eigen vermogensrekening”, 0 (deed in Dutch)
2023
31-12
Financial Weakest financial yearnet -€216,728
Net result drops to -€216,728, the lowest in the series; recovery starts the following year.
22-07
NBB filing Annual accounts filed
financial year 2022 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
2 of 4 deeds read
About the unread acts

Of the 4 Belgian Official Gazette deeds we know for this company, 2 have been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

We would like to set cookies. That happens only with your consent. What we measure